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An ACE inhibitor reduces Th2 cytokines and TGF-b1 and TGF-
b2 isoforms in murine lupus nephritis.
Background. Angiotensin-converting enzyme (ACE) in-
hibitors, such as captopril, are used to control hypertension. In
patients and animals with primary nephropathies, these agents
improve renal function more than that would be expected from
their control of hypertension. Here, we examine the effects of
treatment with captopril on lupus nephritis and discuss the po-
tential mechanism(s) by which this agent exerts its renoprotec-
tive effects.
Methods. Lupus-prone, NZB/NZW F1 and MRL-lpr/lpr,
mice were treated with captopril or with a control antihyper-
tensive agent, verapamil. Mice were monitored for nephritis,
and their sera and tissues analyzed for cytokine and transform-
ing growth factor-b (TGF-b) expression.
Results. Captopril treatment delayed the onset of proteinuria
when administered to prenephritic mice, whereas verapamil
did not. Captopril treatment also retarded disease progression
when given to lupus mice that had early disease, and even re-
versed severe proteinuria in at least some older animals with
advanced disease. It reduced chronic renal lesions, but had no
effect on autoantibody production. The improvement in renal
disease correlated with reduced TGF-b expression, particularly
of the TGF-b1 and TGF-b2 isoforms, in the kidneys. Interest-
ingly, in vivo or in vitro exposure to captopril reduced splenic
levels of type 2 cytokines, interleukin (IL)-4 and IL-10, suggest-
ing a possible role of the immune system in captopril-mediated
disease modulation.
Conclusion. Since type 2 cytokines are known to promote lu-
pus glomerulosclerosis, decreased IL-4 and IL-10 production in
captopril-treated mice may be related to this agent’s renopro-
tective effects. We argue here that ACE inhibitors not only act
as selective TGF-b inhibitors, but also as selective immunomod-
ulators, to improve lupus nephritis.
Development of kidney disease is one of the most
serious consequences of systemic lupus erythematosus
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(SLE). Lupus nephritis is believed to result mostly from
renal deposition of autoantibodies and immune com-
plexes [1], which in turn triggers an acute inflammatory
response characterized by activation of leukocytes and re-
nal parenchymal cells. This activation is accompanied by
the production of cytokines and growth factors. Nephri-
tis may then progress to a chronic phase, characterized
by excessive deposition of collagen and other extracellu-
lar matrix macromolecules [2]. The mechanistic changes
underlying this process of renal fibrosis and its eventual
progression to end-stage renal disease (ESRD) are not
adequately understood.
Several lines of evidence suggest that the transform-
ing growth factor-b (TGF-b) contributes to the develop-
ment of fibrosis in various tissues, including kidneys [3–5].
Recent studies also implicate type 2 cytokines, such as in-
terleukin (IL)-4, IL-10, and IL-13, in the development
of tissue fibrosis [6, 7]. For example, we have recently
reported that IL-4 contributes to the development of
glomerulosclerosis in murine lupus [8]. In vivo neutral-
ization of IL-4 by anti-IL-4 antibody treatment markedly
reduces chronic renal disease in lupus-prone NZM.2410
mice. In addition, NZM.2410 mice rendered deficient in
STAT6, a transcription factor involved in the production
and function of type 2 cytokines, are completely protected
from the development of glomerulosclerosis [8].
Kidneys contain all the components of the renin-
angiotensin system, the substrate (angiotensinogen), the
enzymes involved in the synthesis of angiotensins, and
angiotensin receptors [9]. Ample evidence supporting a
possible role for the renin-angiotensin system in renal
fibrosis includes (1) angiotensin II stimulates fibroblast
activation [9–11]; (2) angiotensin II receptor knockout
mice are protected from chronic kidney disease [12, 13];
and (3) agents that inhibit the production or function
of angiotensin II, that is, angiotensin-converting enzyme
(ACE) inhibitors and angiotensin receptor blockers, re-
spectively, reduce or even reverse the development of
chronic kidney lesions in murine models of primary renal
diseases [5, 9, 14].
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The role of the renin-angiotensin system and the ef-
fects of angiotensin II inhibitors on the development of
SLE have not been well studied. One line of evidence
that supports a role for this system in the development
of lupus nephritis comes from studies of ACE gene poly-
morphisms, in which patients with certain ACE genotypes
present with severe nephritis [15]. Additionally in three
uncontrolled case series each involving less than 14 pa-
tients, treatment with captopril improved lupus nephritis
[16–19]. In addition, using animal models of lupus, one
laboratory has also reported beneficial effects of capto-
pril [20–22].
Mechanisms by which angiotensin II inhibitors exert
a protective effect against renal injury are not well un-
derstood. The effect appears to be independent of their
antihypertensive effect [23]. It has been suggested that
the angiotensin II inhibitors decrease renal fibrosis by
restricting the angiotensin II–stimulated production of
TGF-b [5, 24, 25], although it remains unclear which par-
ticular isoform (i.e., TGF-b1, TGF-b2, or TGF-b3) is in-
volved. Since immune cells also express angiotensin II
and angiotensin II receptors [26–29], angiotensin II in-
hibitors may also directly affect immune functions [30,
31] and thus regulate immune-mediated kidney diseases.
Here, we have examined the clinical outcome and ef-
fect(s) of treatment with an ACE inhibitor, captopril, in
murine models of SLE. Specifically, we have evaluated
the effects of captopril on the development and progres-
sion of nephritis, autoantibody production, and cytokine
responses, which are implicated in the development of
tissue fibrosis. Our results show that captopril treatment
reduces the development of chronic renal lesions, with-
out any apparent effect on autoantibody production. The
observed improvement in renal disease is associated with
reduced expression of the TGF-b isoforms, TGF-b1 and
TGF-b2, in the kidneys, and with decreased production of
cytokines IL-4 and IL-10 in spleen cells. We propose that
the beneficial effect of ACE inhibitors on renal disease
is due to a combination of both their local reduction of
TGF-b expression and on immune system type 2 cytokine
production.
METHODS
Animals
NZB, NZW, BALB/c, and B10.Pl mice were originally
obtained from the Jackson Laboratories (Bar Harbor,
ME, USA) and were intercrossed to generate (NZB
× NZW) F1 [BWF1], (BALB/c × NZW) F1 [CWF1]
and (NZB × B10.Pl) F1 [BPF1] mice. MRL-lpr/lpr mice
were purchased from the Jackson laboratories. BWF1 and
MRL-lpr/lpr mice develop glomerulonephritis, which his-
tologically is similar to the disease seen in humans with
SLE [8, 32]. CWF1 and BPF1 mice, which carry the major
histocompatibility (MHC) class II molecules identical to
those in BWF1 mice, do not develop a lupus-like autoim-
mune disease [33].
Treatment
Mice were treated with captopril, verapamil, or were
left on normal drinking water. Captopril (Squibb & Sons,
Princeton, NJ, USA) and verapamil (Geneva Pharma-
ceutical, Inc., Broomfield, CO, USA) were dissolved in
drinking water at a concentration of 0.2 and 0.5 mg/mL,
respectively. The daily dosage was 32 mg/kg body weight
for captopril and 72 mg/kg for verapamil, assuming a daily
fluid intake of 5 mL. These doses of the two antihyper-
tensive drugs were chosen to achieve a similar level of
systolic blood pressure.
Assessment of renal disease
Animals were monitored for proteinuria and were bled
for measurements of serum TGF-b and autoantibodies.
Proteinuria was estimated by examination of fresh urine
using Albustix (Ames, Elkhart, IN, USA) on a scale of
0 to 4, where 0/trace = nondetectable, 1 = 30 mg of
protein/dL, 2 = 100 mg of protein/dL, 3 = 300 mg
of protein/dL, and 4 ≥ 2000 mg of protein/dL. Severe
proteinuria was defined as ≥ 300 mg/dL on two consecu-
tive occasions [32].
Blood pressure measurement
Blood pressure was measured by tail cuff using BP-
2000 Computerized Blood Pressure Analysis System for
rodents (Visitech Systems, Raleigh, NC, USA). Blood
pressure was recorded daily for 4 to 5 consecutive days.
Data are expressed as the mean of eight to ten successful
measurements.
Kidney histology
Kidney tissues were fixed in 4% paraformaldehyde and
processed into paraffin. Four micrometer sections were
cut, stained with hematoxylin and eosin (H&E), periodic
acid-Schiff (PAS), Jones silver, and Masson’s trichrome,
and scored by two of us (R.R.S. and D.A.A.) in a blinded
fashion for various morphologic lesions on a 0 to 3 scale,
where 0 = absence of lesions; 0.5 = minimal lesions (less
than 10%); 1 = lesions involving up to 30% of the com-
ponent considered; 2 = lesions involving 30% to 60%;
and 3 = lesions involving >60% of the component. The
following components were studied: (1) glomerular activ-
ity score (GAS) that includes glomerular proliferation,
karyorrhexis, fibrinoid necrosis, inflammatory cells, cel-
lular crescents and hyaline deposits; (2) tubulointerstitial
activity score (TIAS) that includes interstitial inflamma-
tion, tubular cell necrosis and/or flattening, and epithe-
lial cells or macrophages in tubular lumen; (3) chronic
lesions score (CLS) that includes glomerular sclerosis
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and/or scarring, fibrous crescents, tubular atrophy, and
interstitial fibrosis; and (4) vascular lesion score (VLS)
that includes arterial/arteriolar lesions. The raw scores
assigned by the two readers were averaged to obtain a
mean score for the each individual feature. These mean
scores were then summed to obtain the average score
for each of the four main indices (GAS, TIAS, CLS, and
VLS), which were then summed to obtain a composite
kidney biopsy score.
Renal immunofluorescence and immunohistochemistry
Kidneys were embedded in Tissue-Tec OCT medium
(Miles Inc., Elkhart, IN, USA) and frozen in liquid ni-
trogen. Four micrometer thick sections were fixed in
0.3% cold (4◦C) acetone for 10 minutes, washed
with phosphate-buffered saline (PBS)/0.05%-Tween, and
blocked with PBS/2% bovine serum albumin (BSA) for 1
hour. Sections were stained with fluorescein-conjugated
goat anti-mouse IgG (Sigma Chemical Co., St. Louis, MO,
USA) or antirat fibrinogen (ICN Pharmaceuticals, Inc.,
Aurora, OH, USA) for 1 hour. For immunohistochem-
istry, fixed kidney sections were exposed to 0.3% hy-
drogen peroxide to quench endogenous peroxidase and
blocked with PBS/2% BSA for 1 hour. Sections were then
incubated with biotinylated rat antihuman/mouse TGF b
(PharMingen, San Diego, CA, USA) for 2 hours at room
temperature, followed by incubation with horseradish
peroxidase-conjugated streptavidin (Zymed) for 1 hour
in a humidified chamber. Slides were next stained with
orthophenylene diamine, counterstained with H&E, and
were scored in a blinded fashion for the intensity of stain-
ing in 25 to 30 glomeruli, tubules, interstitium, and blood
vessels on a scale of 0 to 3, where 0 = negative, 1 = mild
scattered staining, 2 = moderate staining, and 3 = strong
diffuse staining.
Measurement of anti-dsDNA antibodies
Serum anti-dsDNA antibodies were measured by
enzyme-linked immunosorbent assay (ELISA), as previ-
ously described [32]. IgG anti-double-stranded (ds)DNA
titers measured are expressed as units per mL (U/mL), us-
ing a reference standard of pooled serum from 8-month-
old BWF1 mice.
Spleen cell culture
Spleen cells (5 × 106 per mL) were cultured for 48 to
60 hours in a serum-free medium (AIM) (Gibco, Grand
Island, NY, USA) for TGF-b assays or in RPMI medium
supplemented with 10% fetal calf serum (FCS), 2 mmol/L
L-glutamine, 4 mmol/L nonessential amino acid, and 1
mmol/L Hepes.
Measurement of cytokines
Cytokine levels in culture supernatants were deter-
mined by ELISA, using monoclonal antibody pairs and
recombinant cytokines purchased from PharMingen, as
described previously [34]. Total and endogenously active
TGF-b1 were assayed on acid-treated (for total TGF-b1)
and untreated (for endogenously active or free form of
TGF-b1), samples, respectively, by sandwich ELISA us-
ing a kit purchased from Promega (Madison, WI, USA)
following manufacturer’s instructions. In brief, multiwell
ELISA plates (Maxisorp; Nunc, Naperville, IL, USA)
were coated with 100 lL per well of an anti-TGF-b1 mon-
oclonal antibody in carbonate buffer (pH 9.6) overnight
at 4◦C. Plates were washed three times with Tris-HCl (pH
7.6) containing 0.05% Tween 20, followed by blocking for
35 minutes at 37◦C, prior to the addition of samples and
recombinant TGF-b1 standard. Plates were then incu-
bated for 90 minutes at room temperature and washed
five times before the addition of 100 lL per well of an
anti-TGF-b1 antibody. After 2 hours of incubation at
room temperature, 100 lL of a goat antirabbit IgG con-
jugated to horseradish peroxidase was added to each
well and the plates were incubated for an additional
2 hours. Afterward, they were washed six times and
100 lL peroxidase substrate/tetramethyl benzidine
(TMB) solution was added. Fifteen minutes later, the re-
action was stopped with 1 mol/L phosphoric acid and the
optical density (OD) 450 nm was read using an ELISA
reader.
Detection of TGF-b in kidney eluates
Frozen kidneys were homogenized in Hank’s balanced
salt solution, filtered through a 0.22 lm pore mem-
brane and centrifuged at 1200 × g to remove cell debris.
TGF-b levels were measured using a TGF-b–specific kit
(Promega) as described above. Eluates were analyzed for
total protein concentration using the BCA Kit (Pierce,
Rockford, IL, USA). Results are expressed as the TGF-
b :total protein ratio in the kidneys.
Riboprobes
The riboprobes were synthesized from vectors contain-
ing fragments of murine cDNA for TGF-b1 (974 bp; nu-
cleotides 421-1395) [35], TGF-b2 (442 bp; nucleotides
1511-1953) [36], and TGF-b3 (609 bp; nucleotides 831-
1440) [37] (kind gifts from Dr. Harold Moses, Vander-
bilt University, Nashville, TN). To generate antisense
(sense) riboprobes, plasmid murine (pm)TGF-b plasmids
were linearized using HindIII (EcoRI) for pmTGF-b1,
EcoRI (XhoI) for pmTGF-b2, and HindIII (XbaI) for
pmTGF-b3. T7 (SP6), SP6 (T7), and T7 (SP6) RNA poly-
merases were used to synthesize digoxigenin-labeled uri-
dine triphosphate (DIG-UTP) antisense (sense) probes
for TGF-b1, TGF-b2, and TGF-b3, respectively, us-
ing the manufacturer’s instructions (Roche Molecular
Biochem, Indianapolis, IN, USA). All riboprobes were
digested to an average length of 100 to 200 nucleotides
by controlled alkaline hydrolysis before use in the in situ
hybridization analysis.
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In situ hybridization for detection of TGF-b1, TGF-b2,
and TGF-b3 mRNA in the kidneys
Four micrometer paraffin kidney sections were cut, de-
paraffinized, treated with proteinase K (20 lg/mL) for
5 minute at room temperature, followed by successive
washes in Tris-glycine, 2 × standard sodium citrate (SSC),
and 0.1 mol/L triethanolamine/0.25% acetic anhydride,
pH 8.0, for 10 minutes at room temperature each time.
Afterward, the sections were washed again in 2 × SSC,
and then dehydrated by 5-minute incubations in 70%,
95%, and 100% ethanol. The mouse TGF-b riboprobes
were synthesized as described above using 4-thio uri-
dine monophosphate (UMP). Sense and antisense RNA
probes were generated, labeled using a S35 RNA label-
ing kit, denatured by boiling for 10 minutes, cooled on
ice for 5 minutes, then added to hybridization buffer
[50% formamide/2 × SSC/1 × Denhardt’s/20% dextran
sulfate/0.75 mg/mL Herring sperm DNA (Sigma Chem-
ical Co.)/0.75 mg/mL tRNA (Gibco BRL)] at 6 ng/lL,
and the hybridization mixture was incubated with tissue
overnight at 42◦C to 45◦C. The tissues were then washed
three times with 1 × SSC for 10 minutes each time at
50◦C, treated with RNase A (50 lg/mL) and RNase T1
(40 units) for 30 minutes at 37◦C. This was followed by two
10-minute washes in 2 × SSC at 50◦C and two 60-minute
washes in 2 × SSC and dithiothreitol (DTT)/formamide,
one 10-minute wash in 0.5 × SSC and DTT, and two 10-
to 30-minute washes in 0.1 × SSC and DTT at 55◦C.
After further dehydration and air drying of tissues, the
S35 label in the samples was detected by autoradiogra-
phy, with the slides being exposed to NTB-2 emulsion
(Kodak, Rochester, NY, USA) for 7 to 14 days, as de-
scribed by the manufacturer. Sections were counter-
stained with H&E, mounted in permount, and air-dried
and examined using a light microscope.
Statistical analysis
Differences in cytokine and antibody production be-
tween groups were compared using Graphpad InState or
SAS softwares. Depending on the distribution of contin-
uous data, Student t test or a Mann-Whitney U statistic
was used for analysis. Differences of categorical data be-
tween groups were assessed using the two-sided Fisher’s
exact test and the log-likelihood ratio test. Differences
in the time to onset of proteinuria between groups was
tested for signficant differences using survival analysis
and log-rank tests.
RESULTS
Treatment of prenephritic BWF1 mice with captopril
inhibits the development of chronic lupus nephritis
To assess the effect of ACE inhibitors on the de-
velopment of spontaneous lupus nephritis, 16-week-old
prenephritic BWF1 mice that tested positive for circulat-
ing IgG anti-dsDNA antibodies, but had no detectable
proteinuria, were treated with captopril dissolved in nor-
mal drinking water. Control mice received verapamil or
were left on normal drinking water. Mice were mon-
itored weekly for proteinuria (Fig. 1A) and sacrificed
after 14 weeks of treatment to determine the effect of
treatment on renal histology (Fig. 1B and C). Dosages
of captopril and verapamil were adjusted to achieve a
similar level of tail-cuff blood pressure (Fig. 1D). As
shown in Figure 1A, development of severe protein-
uria was delayed in captopril-treated mice as compared
with verapamil-treated or untreated control animals. By
30 weeks of age, six of ten untreated and five of ten
verapamil-treated mice, but only one of 12 captopril-
treated mice, had developed severe proteinuria (P <
0.02).
At 30 weeks of age, kidneys were harvested from the
treated and control mice and stained with H&E, PAS,
and Masson’s trichrome. Stained sections were scored
for active and chronic lesions using a kidney biopsy scor-
ing system described in the Methods section. We found
that while activity and vascular lesion scores, GAS, TIAS,
and VLS, were not significantly different between the
captopril-treated and control mice, chronic lesions (CLS)
were significantly lower in captopril-treated mice than in
both control groups (P < 0.05) (Fig. 1B). In particular,
glomerulosclerosis, interstitial fibrosis, and tubular atro-
phy were markedly decreased in captopril-treated mice
as compared with control animals (Fig. 1C, and data not
shown).
A selective decrease in chronic renal lesions prompted
us to further examine the effect of captopril treatment
on renal matrix deposition. Frozen kidney sections
were stained with a conjugated antifibrinogen antibody.
The average staining scores were significantly lower
in captopril-treated mice than in the control animals
(Fig. 1B).
These data suggest that ACE inhibitors can delay the
onset of proteinuria by selectively preventing the devel-
opment of chronic renal lesions, including glomeruloscle-
rosis and tubulointerstitial fibrosis.
Captopril treatment retards and even reverses renal
disease in MRL-lpr/lpr and BWF1 mice
We next asked the question whether captopril treat-
ment can retard the development of lupus nephritis in
lupus-prone mice that have already developed disease.
Fifteen-week-old MRL-lpr/lpr mice that had already be-
gun to develop kidney disease were treated with captopril
and monitored for the progression of disease. As shown
in Figure 2A, while all nine untreated mice progressed to
advanced renal disease and died, four of six captopril-
treated mice remained aproteinuric during 3 months
of follow up. The proportion of animals with severe
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Fig. 1. Captopril treatment delays the on-
set of proteinuria and inhibits chronic lupus
nephritis in BWF1 mice. Sixteen-week-old
BWF1 mice were treated with captopril (N =
12), verapamil (N = 10), or left on normal
drinking water (N = 10) for 14 weeks. (A)
Mice were monitored for proteinuria by Al-
bustix. Results are expressed as the cumu-
lative frequency of severe proteinuria (≥3+
on two consecutive occasions). ∗P < 0.02
captopril-treated versus verapamil-treated or
untreated groups. (B) At 30 weeks of age,
mice were sacrificed to analyze the effect of
treatment on renal histology. Individual kid-
ney biopsy scores, including glomerular activ-
ity score (GAS), chronic lesion score (CLS),
tubulointerstitial activity score (TIAS), and
vascular lesion score (VLS) are expressed
as the mean ± SE. Immunofluorescence in
glomeruli, blood vessels and tubules were
scored on a scale of 0 to 3 in kidney sec-
tions stained with fluoroscein isothiocyanate
(FITC) antifibrinogen; the individual scores
were summed to obtain a fibrinogen score
(FibS). ∗P < 0.05. (C) Representative re-
nal sections stained with hematoxylin and
eosin (H&E) (upper panel), periodic acid-
Schiff (PAS) (middle panel), and Masson’s
trichrome (lower panel) are shown. (D) Blood
pressure measurements are shown as the
mean ± SE of the mean tail-cuff pressure on
the 4th day of consecutive daily recordings.
∗P < 0.05 to < 0.01 in the untreated versus
captopril- or verapamil-treated mice.
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Fig. 2. Treatment with captopril retards and
even reverses lupus renal disease in some
mice. MRL-lpr/lpr (A) or BWF1 (B and C)
mice were treated with captopril. Animals
treated with verapamil (B) or those left on
normal drinking water (A and C) served as
controls. Results are expressed as the mean
Albustix proteinuria readings from two con-
secutive assessments (0 = negative; trace
<30 mg/dL; 1 = 30 mg/dL; 2 = 100 mg/dL; 3 =
300 mg/dl; and 4 = 2000 mg/dL). Each line rep-
resents an individual mouse. (A) Treatment of
15-week-old MRL-lpr/lpr mice with captopril
retards the development of nephritis (N = 9
untreated and 6 captopril-treated mice). Mice
were sacrificed when they appeared to be ter-
minally sick (×). (B) Five-month-old BWF1
mice were treated with captopril (N = 8) or
verapamil (N = 9) for 4 weeks. After discon-
tinuing the treatment, five mice in each group
were monitored for another 3 weeks. Abbre-
viationa are: Pre, at treatment onset; post, im-
mediately after completing treatment; Tt stop,
treatment stop. (C) Treatment of BWF1 mice
having advanced renal disease. Nine to 12-
month-old BWF1 mice that had proteinuria
readings of ≥100 mg/dL for two consecutive
weeks were randomized to receive captopril
or normal water for 2 weeks. Results are rep-
resentative of two independent experiments.
Abbreviations are: pre, at treatment onset;
post, after treatment.
proteinuria (≥300 mg/dL on two consecutive occasions)
was significantly lower in the treated group than in the
control untreated group (P < 0.05). While kidneys from
all untreated mice showed advanced lesions, four of six
captopril-treated mice had markedly reduced glomeru-
lar and tubular lesions (data not shown). Log-rank anal-
ysis supports a significantly increased survival among
captopril-treated mice as compared to control animals
(P < 0.01).
Similar results were obtained in 5-month-old female
BWF1 mice that had high levels of IgG anti-dsDNA
antibodies and occasionally proteinuria at the onset of
treatment. At the end of 4 weeks of treatment, mean
proteinuria levels were lower in captopril-treated than
in verapamil-treated control animals (Fig. 2B). Three of
nine mice in the verapamil-treated group, but none in the
captopril-treated group, developed severe proteinuria at
the end of treatment (P < 0.05). Upon discontinuation
of the treatment, proteinuria reoccurred in the captopril-
treated group (Fig. 2B). Taken together, these data sug-
gest that captopril treatment may halt or even reverse
renal disease in BWF1 mice having early disease.
To further examine whether captopril treatment could
reverse advanced disease, aged (9 to 12 months old) and
nephritic (>100 mg/dL proteinuria for at least 2 consec-
utive weeks) BWF1 mice were treated with captopril for
2 weeks (Fig. 2C). Nonparametric analyses were per-
formed to compare proteinuria grades before and after
treatment as well as to compare the change in protein-
uria grades from the pretreatment level. Remarkably,
the severity of proteinuria decreased in some captopril-
treated mice, while untreated mice for the most part ex-
perienced worsening of proteinuria. At the end of treat-
ment, animals in the captopril group had significantly
lower grades of proteinuria than animals in the control
group (P < 0.05). The change (decrease) in proteinuria
grades was also greater in captopril-treated mice than in
control animals (P < 0.05).
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Fig. 3. Effect of captopril on serum IgG anti-dsDNA antibody levels.
16-week-old BWF1 mice were treated with captopril or verapamil or
were left on normal drinking water (n = 10–12 mice per group). Their
sera were collected once a month for detection of IgG anti-dsDNA
antibody levels. Results are shown as the mean ± SE U/mL. Data shown
are representative of six independent experiments.
Serum autoantibody levels remain elevated
in captopril-treated lupus mice
Studies in humans and mice with SLE suggest that kid-
ney damage in SLE is caused, at least in part, by IgG anti-
DNA antibodies [1]. Therefore, we examined whether
the improvement in lupus nephritis in captopril-treated
mice is related to the reduction of serum autoantibody
levels. We found that captopril treatment had no signif-
icant effect on serum IgG anti-dsDNA antibody levels
in BWF1 and MRL-lpr/lpr mice in six of seven experi-
ments (Fig. 3, and data not shown). In the remaining one
experiment in BWF1 mice and in another experiment in
normal BPF1 mice, captopril-treated animals had mod-
estly increased levels of IgG anti-dsDNA antibodies, but
the differences were not statistically significant (data not
shown). There was also no significant effect of captopril
treatment on serum levels of rheumatoid factor and anti-
cardiolipin autoantibodies and on IgG anti-dsDNA anti-
body production by spleen cells in vitro (data not shown).
Thus, captopril treatment improves lupus nephritis by
mechanism(s) other than the reduction of autoantibody
production.
Captopril treatment selectively decreases the mRNA
expression of the TGF-b1 and TGF-b2, but not of
the TGF-b3 isoform, in the kidneys of lupus mice
In primary chronic nephropathy models, angiotensin II
inhibitors are believed to exert renoprotective effect via
their inhibitory effects on TGF-b production [5]. It is not
known if a similar mechanism is operative in renal protec-
tion conferred by captopril treatment in lupus. There are
three known mammalian isoforms of TGF-b (i.e., TGF-
b1, -b2 and -b3), all of which signal through the TGF-b
receptors type II and type I, and Smad signaling proteins
[38]. It is unclear which of the three TGF-b isoforms con-
tributes the most to the development of kidney disease.
Captopril treatment may differentially affect the expres-
sion or activity of one or more isoforms of this important
growth factor, thus leading to improvement in kidney dis-
ease. Here we used in situ hybridization analysis to local-
ize and define the sites of TGF-b isoform expression in
the kidneys from captopril-treated and untreated mice.
Sixteen-week-old BWF1 mice were treated with capto-
pril for 14 weeks. Their kidneys were harvested at the
end of treatment and examined for mRNA expression
and localization for the three TGF-b isoforms. Represen-
tative sections are shown in Figure 4A to C. The resulting
images were also scored semiquantitatively for the ex-
pression of the various isoforms and a summary of scores
is shown in Figure 4D. In the kidneys of untreated BWF1
mice, we detected a strong TGF-b1 mRNA signal in the
glomeruli and lymphoid infiltrates (Fig. 4A, panels A and
C), TGF-b2 mRNA was localized in the periglomeru-
lar region (Fig. 4B, panel A) and in isolated tubular
cells (Fig. 4B, panels C and D), and TGF-b3 mRNA ex-
pression was uniformly distributed in the distal tubules
(Fig. 4C, panels A, C, and D). In captopril-treated mice,
TGF-b1 mRNA expression was markedly decreased in
the glomeruli of all treated animals and modestly de-
creased in the lymphoid infiltrates. TGF-b2 mRNA ex-
pression in the periglomerular regions was also markedly
decreased, but there was no effect of captopril treatment
on the intense TGF-b2 mRNA signal in isolated tubular
cells. TGF-b3 mRNA expression levels were not signifi-
cantly different between the treated and control animals
(see Fig. 4A to D, panel B). Thus, captopril-treated mice
had a selective reduction in the expression of TGF-b1
and TGF-b2 isoforms only in certain renal structures.
Effect of captopril treatment on TGF-b protein
in the kidneys of lupus mice
We next examined the effect of captopril treatment on
TGF-b protein localization in the kidneys of lupus-prone
mice using immunostaining. In young BWF1 mice with
early nephritis, renal TGF-b localization was lower in
captopril-treated mice than in verapamil-treated animals
(Fig. 5). TGF-b protein localization, however, was not
consistently decreased in captopril-treated mice as com-
pared to untreated control mice, when the treatment was
initiated in older nephritic BWF1 mice (data not shown).
For a more quantitative assessment of kidney TGF-b ex-
pression, we measured TGF-b protein levels in kidney
eluates from captopril-treated and untreated BWF1 mice.
To normalize for the variation in the size of kidney pieces
used, total protein content was determined for each
Albuquerque et al: Captopril effects on lupus nephritis 853
eluate. The levels of total and active TGF-b as well as the
ratios of TGF-b to total protein in kidney eluates showed
a decreasing trend in captopril-treated mice as compared
to untreated mice, but the differences did not reach statis-
tical significance (data not shown). Thus, captopril treat-
ment inhibited renal TGF-b protein expression in young
BWF1 mice, but had minimal effect on TGF-b protein
expression in older BWF1 mice.
Effect of captopril treatment on circulating levels
of TGF-b1
We were concerned that ACE inhibitor treatment may
decrease systemic levels of TGF-b1, which may in turn
aggravate the autoimmune manifestations of lupus [39].
We therefore examined the effect of captopril treatment
on serum levels of TGF-b1 (data not shown). In younger
BWF1 mice, although the captopril treatment had no
effect on total TGF-b1 serum levels, it significantly de-
creased the levels of active TGF-b1 in three independent
experiments. In older BWF1 mice, captopril treatment
had only a minimal (15% to 20% decrease in two exper-
iments; P = NS) or no (in three experiments) effect on
serum levels of active or total TGF-b1. This may be be-
cause TGF-b1 levels were already relatively low to begin
with in these mice.
Effect of captopril treatment on spleen cell production
of TGF-b1
To evaluate the effect of captopril treatment on TGF-
b1 production by lymphoid cells, lupus-prone BWF1
and nonautoimmune CWF1 mice of different ages were
treated with captopril for varying periods (2 to 14 weeks).
At the end of treatment, their spleen cells were cultured
in serum-free medium for 60 hours and supernatants were
evaluated for TGF-b1 levels (data not shown). We found
that the spleen cell production of TGF-b1 was slightly
lower in both BWF1 and CWF1 mice in captopril-treated
group than in the untreated group; none of these differ-
ences were statistically significant, however.
Spleen cell production of type 2 cytokines is decreased
in captopril-treated mice
IL-4 plays an important role in the development
of glomerulosclerosis in lupus-prone mice [8]. Since
captopril-treated mice had a selective decrease in chronic
fibrotic kidney lesions, we reasoned that captopril treat-
ment might reduce kidney disease by reducing the pro-
duction of type 2 cytokines. Indeed, IL-4 and IL-10
levels were significantly reduced in spleen cell cultures
from captopril-treated BWF1 mice as compared with un-
treated control animals (Fig. 6). There was no statistically
significant effect of captopril treatment on the levels of
the type 1 cytokines, interferon-gamma (IFN-c) or IL-2.
The inhibitory effect of captopril treatment on splenic
IL-4 and IL-10 production was observed in BWF1 mice
of all ages (Fig. 6 and data not shown).
To exclude the possibility that the decrease in type 2
cytokine production in captopril-treated mice was sec-
ondary to improvement in lupus in BWF1 mice, we
treated nonautoimmune BPF1 and CWF1 mice with cap-
topril. As shown in Figure 7, IL-4 levels were decreased in
captopril-treated mice of both strains. This suggests that
ACE inhibitors may intrinsically affect the production of
type 2 cytokines.
In vitro exposure to captopril reduces spleen cell
production of IL-4, IL-10, and TGF-b
To further investigate the possibility that the captopril
may have a direct modulatory effect on immune cells, we
cultured spleen cells from lupus-prone BWF1 and normal
CWF1 mice with increasing concentrations of captopril in
vitro and determined the levels of IL-4, IL-10, IFN-c, and
active and total TGF-b1 (Fig. 8). Results show that IL-
4 production was dramatically and consistently reduced
in the presence of captopril in a dose-dependent man-
ner in both lupus-prone and normal animals (Fig. 8A).
IL-10 production was also consistently reduced by two-
to threefold in a dose-dependent manner in both lupus-
prone and normal animals (Fig. 8B). In contrast, IFN-c
levels were slightly increased or unaffected (Fig. 8C and
D). Levels of total and active TGF-b1 were reduced only
in captopril-exposed cultures from lupus-prone mice, but
not from the control animals (Fig. 8E). These observa-
tions suggest that captopril treatment may directly affect
the functions of immune cells and that IL-4 production, in
particular, is profoundly affected by captopril treatment.
DISCUSSION
In this article, we describe the effects that captopril
treatment has on the development of lupus nephritis in
murine models of SLE. Captopril treatment was found
to delay the onset of proteinuria, and retard the progres-
sion, and even reverse advanced renal disease by reducing
the degree of glomerulosclerosis and renal fibrosis. The
beneficial effect of captopril treatment is associated with
a previously unreported cytokine modulatory effect of
captopril (i.e., increasing captopril dosage is correlated
with a reduction in the production of IL-4 and IL-10 by
spleen cells). This effect was detected in both lupus-prone
strains and normal stains. Additionally, captopril treat-
ment differentially reduced the renal expression of cer-
tain TGF-b isoforms in specific locations in the kidneys
of lupus-prone mice. Such an effect of ACE inhibitors on
TGF-b isoform expression has not been reported previ-
ously to the best of our knowledge.
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Fig. 5. Immunohistochemistry for renal
TGF-b protein expression in lupus mice.
Five-mo-old BWF1 mice were treated
with captopril. At the end of 6 weeks of
treatment, their kidneys were stained with a
conjugated anti-TGF-b1 Ab. Representative
kidney sections from untreated control and
captopril-treated mice are shown. Staining
in glomeruli, tubules and blood vessels was
separately scored on a scale of 0–3 and
summed to obtain a single staining score for
each mouse. Results are shown as the mean
± SE of staining scores from 9 mice in each
group (∗P < 0.05).
Upon signaling through the angiotensin II receptor,
angiotensin II stimulates fibroblasts [10, 25], suggesting
a possible role of angiotensin II in tissue fibrosis, includ-
ing glomerulosclerosis and renal tubulointerstitial fibro-
sis. Consistent with this role of angiotensin II, germline
deletion of angiotensin II or treatment with angiotensin II
inhibitors reduces or even reverses the development of
glomerulosclerosis in models of primary renal diseases
[5, 9, 12–14] and in autoimmune diseases such as lupus
[16–22] (Figs. 1 and 2).
The mechanisms by which angiotensin II inhibitors
exert antifibrotic and renoprotective effect in glomeru-
lonephritis and other models of renal injury are not well
understood. It is known that angiotensin II stimulates
TGF-b production [24, 25] and its conversion from the
latent to a bioactive form [11]. Moreover, angiotensin
II–induced extracellular matrix expression is blocked
by anti-TGF-b antibody or TGF-b antisense oligonu-
cleotides [24, 25]. Thus, angiotensin II–mediated stimula-
tion of TGF-b production may play an important role in
the development of glomerulosclerosis and renal fibro-
sis. Treatment with angiotensin II inhibitors may halt this
process by restricting the production of TGF-b . In lu-
pus mice, however, captopril treatment had only a mod-
est effect on total or systemic TGF-b protein expression;
a small decrease in TGF-b was only detected in lupus-
prone mice when treatment was initiated at an early age
but was not detected if the treatment was delayed until
after the mice exhibited full-blown nephritis (Fig. 5, and
data not shown). One possibility is that the effect of cap-
topril on TGF-b may not be apparent in lupus-prone mice
as these mice undergo spontaneous changes in TGF-b
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 4. In situ hybridization for the detection of TGF-b1, TGF-b2, and TGF-b3 isoforms in kidneys of lupus mice. In situ hybridization was used to
define the sites of TGF-b1, TGF-b2, and TGF-b3 mRNA expression in the kidneys of captopril-treated and untreated control animals. 16-week-old
female BWF1 mice were treated with captopril for 14 weeks. At the end of treatment, their kidneys were analyzed for mRNA expression of the
three TGF-b isoforms. Representative kidney sections from the untreated control [panels A, C and D in (A to C)] and captopril-treated mice [panel
B in (A to C)] are shown. A, B and D, dark field; C, bright field. (A) TGF-b1 mRNA expression. Note intense expression in the glomeruli (G; see
A and C) and lymphoid infiltrates (see A) in the kidneys of untreated mice, but not in the kidney of treated mice (B). The lack of staining with
the control sense probe is shown in D. (B) TGF-b2 expression is noted in the periglomerular region (A) and isolated tubules (C and D) of kidneys
from untreated mice (see arrow), but not in the kidneys of treated mice (B). (C) TGF-b3 is expressed uniformly in distal tubules of kidneys from
both untreated (A, C, D) and treated (B) mice; no difference is noted between the treated and control mice. (D) Kidney sections from the treated
and control mice were also scored for TGF-b1, TGF-b2, and TGF-b3 mRNA expression on a scale of 0–3, where 0 = no expression, 1 = mild, 2 =
moderate, and 3 = marked expression. ∗P < 0.05; ∗∗P < 0.01. Glm = glomerular; Lym = lymphoid infiltrates; PG = periglomerular; Tub = tubular.
expression [33] (manuscript in preparation). Alterna-
tively, the effect of ACE inhibitors on TGF-b expression
may be restricted to certain TGF-b isoforms and may oc-
cur only in certain locations in the target organ (i.e., in the
kidneys of affected mice). Indeed, we found that captopril
treatment markedly reduced TGF-b1 expression in the
glomeruli and TGF-b2 expression in the periglomerular
region, but only modestly decreased TGF-b1 expression
in infiltrating cells, and had little or no effect on TGF-
b2 expression in isolated tubules. TGF-b3 isoform ex-
pression was generally unaffected by captopril treatment
(Fig. 4). Such differential effects suggest that the three
TGF-b isoforms may play unique and non-overlapping
roles in the development of lupus nephritis. These obser-
vations are in agreement with genetic data indicating that
in animal knockout models for the individual TGF-b iso-
forms, differential phenotypes are seen [40], suggesting
that the three TGF-b isoforms have different functions
in vivo.
Interestingly, TGF-b1 mRNA expression was detected
mostly in glomeruli and lymphoid infiltrates in the kid-
neys of BWF1 mice (Fig. 4A), whereas TGF-b1 protein
was found to localize primarily in tubules (Fig. 5) except
in early stages of disease when TGF-b1 protein was also
detected in glomeruli (data not shown). The reason for
this discrepancy is unclear. One possibility is that TGF-b1
is mainly produced in glomeruli and lymphoid infiltrates;
the secreted TGF-b1, however, may drain and localize in
tubules where we find its maximal staining.
We have recently described that TGF-b–producing T
cells derived from normal animals inhibit anti-DNA an-
tibody production [33]. The production and/or induction
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Fig. 6. Effect of captopril treatment on cytokine production in BWF1
mice. 16-week-old female BWF1 mice were treated with captopril for
14 weeks. At the end of treatment, their spleen cells were cultured in
serum-free medium without or with Con A for 48 to 60 hours. Culture
supernatants were tested for IFN-c, IL-2, IL-4, IL-5 and IL-10. Results
from 7 captopril-treated and 5 untreated mice are shown as the mean ±
SE values (∗P < 0.05). Similar results were obtained in four independent
experiments performed in BWF1 mice of different ages, which were
treated for 2 to 14 weeks.
0
0.5
1
1.5
n
g/
m
L
NT Cap
CWF1 mice
A
IFN-γ
0
4
8
12
16
n
g/
m
L
NT Cap
BPF1 mice
B
0
400
800
1200
pg
/m
L
NT Cap
IL-4
0
50
100
pg
/m
L
NT Cap
Fig. 7. Effect of captopril treatment on cytokine production in non-
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were treated with captopril for 10 and 2 weeks, respectively. At the end
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Fig. 8. Effect of in vitro culture with captopril on cytokine produc-
tion. Spleen cells pooled from three each of lupus-prone BWF1 or non-
autoimmune CWF1 mice were cultured in serum-free medium without
or with Con A and varying concentrations of captopril. Supernatants
were tested for cytokines. Results are shown as the mean triplicate
values of IL-4 (A), IL-10 (B), IFN-c (C) and TGFb1 (E) in Con A-
stimulated cultures or of IFN-c in unstimulated cultures (D). IL-4 and
IL-10 levels were low to undetectable in unstimulated cultures. Note
that IL-4 levels were 9–44-fold lower (∗) and IL-10 levels were 2–3-fold
lower (∗∗) in captopril-exposed cultures than in control cultures in both
BWF1 and CWF1 mice; and total and active TGF-b1 levels were re-
duced by about 2-fold in BWF1 mice only (∗∗). Results represent three
independent experiments.
of such regulatory T cells are defective in lupus mice
[33]. Additionally, TGF-b1–deficient T cells are spon-
taneously activated in vivo [41], which causes severe
multiorgan inflammatory disease in TGF-b1 knockout
mice (reviewed in [40]). We were concerned that if treat-
ment with ACE inhibitors reduces TGF-b production
in the lymphoid and other tissues, it might exacerbate
autoantibody production and promote inflammatory
disease. Contrary to our initial expectations, however,
captopril treatment had only a minimal or no effect
on circulating levels or spleen cell production of TGFb
(data not shown). Moreover, captopril treatment did
not significantly exacerbate autoantibody production in
most lupus-prone and normal mice (Fig. 3, and data not
shown). Drug treatment also did not induce any obvious
inflammatory lesions in lupus-prone (BWF1 and MRL-
lpr/lpr) and normal strains (CWF1 and BPF1 mice).
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As mentioned above, captopril treatment was not
always associated with a significant inhibitory effect
on renal TGF-b expression. In some experiments, im-
provement in glomerulosclerosis and renal fibrosis af-
ter captopril treatment occurred in the absence of any
decrease in TGF-b levels in the experimental animals.
This suggests that the protective effects of ACE in-
hibitors in lupus nephritis might be mediated, at least in
part, through other mechanisms. In this regard, we have
recently found that the cytokine, IL-4, and STAT6, a
transcription factor that mediates the production and
functions of IL-4, play important roles in the develop-
ment of glomerulosclerosis in a lupus-prone strain of
mice [8]. Therefore, we investigated the effect of cap-
topril treatment on the production of type 2 cytokines in
the experiments reported here. We found that almost all
mice treated with captopril exhibited a decrease in IL-4
production by spleen cells (Figs. 6 and 7). Additionally,
captopril-treated mice exhibit a reduction in spleen cell
production of IL-10 (Figs. 6 and 7). It has been reported
previously that IL-10 production is increased in periph-
eral blood cell cultures from patients with SLE and in
serum of BWF1 mice [42]. Furthermore, IL-10 exacer-
bates and anti-IL-10 antibody ameliorates disease in cer-
tain mouse models of lupus [43, 44]. Treatment with an
anti-IL-10 antibody has also been shown to improve dis-
ease in patients with SLE [45]. Thus, reduction in IL-10
production may be partly responsible for the beneficial ef-
fects on renal disease observed here in captopril-treated
lupus mice.
The mechanisms by which decreases in IL-4 and IL-10
production by the immune system may contribute to re-
nal disease improvement in captopril-treated lupus mice
are not clear. IL-4 is known to promote fibroblast prolif-
eration, collagen gene expression, and collagen synthesis
[46–48]. Another type 2 cytokine, IL-13, which is also
significantly increased in lupus-prone mice as compared
with nonautoimmune mice (our unpublished data), can
increase type 1 procollagen synthesis in vitro [49]. Type
2 cytokines have been implicated in the development of
lung fibrosis [6, 7, 49, 50]. Furthermore, IL-4 may serve as
a growth factor for cells that secrete TGF-b [51], which,
in turn, may lead to tissue fibrosis [52]. Significantly, IL-
4 transgenic mice exhibit increased renal TGFb expres-
sion and develop glomerulosclerosis, independent of Ig
deposition [52]. IL-10 may also promote tissue fibrosis by
suppressing the action or expression of type 1 cytokines
and hence tip the balance in favor of type 2 cytokine re-
sponses [6]. It remains to be determined how decreased
IL-4 and IL-10 production modulates the development
of renal disease in captopril-treated mice. In future ex-
periments, we hope to determine the effect of captopril
treatment on the expression of these cytokines and their
receptors in the kidneys, and investigate whether type 2
cytokines, in general, directly affect renal fibrogenesis or
modulate the production of other profibrotic cytokines
and growth factors.
Our observations do not exclude the possibility that
the improvement in renal disease induced by ACE in-
hibitors may reflect their hemodynamic effects. Interest-
ingly, however, emerging evidence suggests a link be-
tween the cytokines, IL-4 and TGF-b , and blood pres-
sure. For example, IL-4 blockade can inhibit the increase
in mean arterial blood pressure in lupus-prone BWF1
mice [53], and overexpression of TGF-b1 protein and
mRNA has been found in patients with essential hyper-
tension (reviewed in [54]). Moreover, an association be-
tween certain polymorphisms in the TGF-b1 gene (e.g.,
the Arg25 allele) and higher blood pressure has been re-
ported (reviewed in [54]). Thus, it is possible that the
cytokine, hemodynamic, and therapeutic effects of ACE
inhibitors may all be interrelated in immune-mediated
kidney diseases.
At least three potential mechanisms may explain the
effect of captopril on the cytokine profile that we ob-
served. First, the changes in cytokine pattern may be sec-
ondary to improvement in disease in lupus mice. This,
however, is unlikely since treatment of normal animals
also resulted in a similar cytokine profile (Fig. 7). Second,
the immunologic effects of captopril could be related to
the sulfhydril group on the compound [22]. Recent re-
ports in primary renal diseases, however, indicate that
angiotensin II receptor blockers and ACE inhibitors that
lack a sulfhydril group also inhibit renal disease through
their effects on growth factors [5, 9, 14, 24], suggesting a
direct role of angiotensin II inhibition in nephritis. Third,
angiotensin II inhibitors may directly influence lymphoid
cells via their effects on angiotensin II, which may influ-
ence immune responses [30, 31]. Evidence suggests that
mononuclear leukocytes synthesize angiotensinogen and
upon activation contain large amounts of angiotensin II
[26, 27]. In addition, it is known that macrophages ex-
press angiotensin receptors [29]. Finally, angiotensin II
inhibitors may directly interfere with T-cell activation and
apoptosis signals [30].
CONCLUSION
We have observed that captopril treatment inhibits the
production of type 2 cytokines in the lymphoid system,
and differentially affects TGF-b isoform expression in the
kidneys of lupus mice. Since type 2 cytokines promote
TGF-b production [51] and exacerbate lupus glomeru-
losclerosis [8, 55], the decreased IL-4 and IL-10 produc-
tion detected here may be related to the renoprotective
effects of ACE inhibitors in lupus nephritis. Our future
investigations will focus on how ACE inhibitors affect
lymphoid cell functions, and how their effect on cytokine
production contributes to the reduction in chronic re-
nal lesions. We propose that angiotensin II may act as a
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bridge in the vascular/angiotensin-immune system axis.
Treatment with angiotensin II inhibitors may modulate
this axis and thus may retard the progression and even-
tual severity of immune-mediated renal and vascular dis-
eases. In conclusion, ACE inhibitors may act both as
systemic immunomodulators of the immune system, hav-
ing a broad effect on immunity and autoimmunity, and as
specific inhibitors of renal TGF-b expression.
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